Massachusetts Financial Services Co. MA Decreases Stock Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Massachusetts Financial Services Co. MA reduced its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 324,002 shares of the company’s stock after selling 7,845 shares during the period. Massachusetts Financial Services Co. MA owned about 0.54% of Health Catalyst worth $2,637,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. lifted its position in shares of Health Catalyst by 6.9% during the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after acquiring an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after acquiring an additional 2,164 shares during the last quarter. Creative Planning lifted its position in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after acquiring an additional 2,486 shares during the last quarter. Finally, Quarry LP lifted its position in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the sale, the chief operating officer now owns 134,899 shares of the company’s stock, valued at $1,036,024.32. This represents a 3.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HCAT has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and issued a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Stephens lifted their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Finally, Citigroup lifted their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Trading Down 0.2 %

Shares of HCAT opened at $8.50 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm’s 50-day moving average is $8.13 and its two-hundred day moving average is $7.29. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The firm has a market capitalization of $517.23 million, a P/E ratio of -6.30 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, research analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.